Evidence mapPaperPMID 37239019Full record

ArticleBiomedicines2023

Dynamics of Gene Expression Profiling and Identification of High-Risk Patients for Severe COVID-19.

Alexander Rombauts, Marta Bódalo Torruella, Gabriela Abelenda-Alonso, Júlia Perera-Bel, Anna Ferrer-Salvador, Ariadna Acedo-Terrades, Maria Gabarrós-Subirà, Isabel Oriol, Carlota Gudiol, Lara Nonell and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Alexander RombautsDepartment of Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL, 08908 Barcelona, Spain.ORCID 0000-0003-0227-5916
Marta Bódalo TorruellaMARGenomics, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.ORCID 0000-0002-5950-4700
Gabriela Abelenda-AlonsoDepartment of Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL, 08908 Barcelona, Spain.
Júlia Perera-BelMARGenomics, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.ORCID 0000-0002-6809-132X
Anna Ferrer-SalvadorCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain.
Ariadna Acedo-TerradesMARGenomics, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Maria Gabarrós-SubiràMARGenomics, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.ORCID 0000-0002-2979-1681
Isabel OriolDepartment of Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL, 08908 Barcelona, Spain.
Carlota GudiolDepartment of Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL, 08908 Barcelona, Spain.
Lara NonellMARGenomics, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
Jordi CarratalàDepartment of Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL, 08908 Barcelona, Spain.ORCID 0000-0003-3209-2563
Hospital Del Mar · ESBellvitge University Hospital · ESInstituto de Salud Carlos III · ESCentre for Genomic Regulation · ES

Funding

Government of Catalonia 20DPS005Instituto de Salud Carlos III 20DPS005Instituto de Salud Carlos III FI18/ 00183
6 · The paper itself

Abstract

The clinical manifestations of SARS-CoV-2 infection vary widely, from asymptomatic infection to the development of acute respiratory distress syndrome (ARDS) and death. The host response elicited by SARS-CoV-2 plays a key role in determining the clinical outcome. We hypothesized that determining the dynamic whole blood transcriptomic profile of hospitalized adult COVID-19 patients and characterizing the subgroup that develops severe disease and ARDS would broaden our understanding of the heterogeneity in clinical outcomes. We recruited 60 hospitalized patients with RT-PCR-confirmed SARS-CoV-2 infection, among whom 19 developed ARDS. Peripheral blood was collected using PAXGene RNA tubes within 24 h of admission and on day 7. There were 2572 differently expressed genes in patients with ARDS at baseline and 1149 at day 7. We found a dysregulated inflammatory response in COVID-19 ARDS patients, with an increased expression of genes related to pro-inflammatory molecules and neutrophil and macrophage activation at admission, in addition to an immune regulation loss. This led, in turn, to a higher expression of genes related to reactive oxygen species, protein polyubiquitination, and metalloproteinases in the latter stages. Some of the most significant differences in gene expression found between patients with and without ARDS corresponded to long non-coding RNA involved in epigenetic control.

Indexed as

ARDSCOVID-19gene expressionprognosisSARS-CoV-2transcriptomics

Identifiers

PMID37239019
PMCPMC10216228
OpenAlexW4378514997

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.